Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Frank Jessen, Axel Rominger et al.|The Lancet Neurology|2013Cited by 185
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiencyRichard L. Wasserman, Johann Bichler, Isaac Melamed et al.|European Journal of Pharmaceutical Sciences|2009Cited by 48